Market Overview:
The global chronic gonadotropin market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of infertility, rising awareness about chronic gonadotropin therapy, and technological advancements in the field of assisted reproductive technologies (ART). The human chronic gonadotropin segment is expected to account for the majority share of the global chronic gonadotropin market in 2018. This segment is anticipated to grow at a CAGR of 5.7% from 2018 to 2030 owing to factors such as increasing incidence of infertility and growing demand for ART procedures.
Product Definition:
A hormone that is produced by the pituitary gland in the brain. It stimulates the production of sperm and testosterone in men, and ovulation and progesterone in women.
Human Chronic Gonadotropin:
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the placenta after implantation of the embryo. It acts as an important growth factor for Sertoli cells and Leydig cells in the testes, leading to increased production of testosterone. hCG levels are usually measured in urine or serum samples taken from patients suffering from delayed puberty or hypogonadism.
Animal Chronic Gonadotropin:
Chronic Gonadotropin (CCG) is a pituitary hormone which controls the release of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). It is also called as “gonadotropin” or “hCG”. CCG has an important role in controlling the menstrual cycle, pregnancy, and lactation.
Application Insights:
The others segment held the largest share of more than 50.0% in 2017. This is attributed to the high unmet medical needs and rising awareness regarding available treatment options for menopausal symptoms, which drives demand for GCCG therapy across other applications such as research institutions and hospital settings.
Animal chronic gonadotropin is used in various species of animals including cattle, swine, dogs, horses and buffaloes among others to stimulate milk production when there are no lactating women or if they have gone through menopause. The use of animal chronic gonadotropin has been prevalent since antiquity owing to its ability to mimic the natural hormones produced by a woman¢â‚¬â„¢s body that regulate processes such as ovulation & fertility in animals much better than synthetic products can do.
Regional Analysis:
North America dominated the global chronic gonadotropin market in 2017. The presence of major players, availability of advanced technologies and rising awareness about available treatment options are some factors attributing to its large share. In addition, increasing prevalence of infertility is also expected to drive growth during the forecast period. According to a study published by National Center for Health Statistics (NCHS), around 6 million women between 15 and 44 years were diagnosed with primary infertility in 2015 which is approximately 12% increase from 2010.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments as well as private sectors coupled with growing investments for development of infrastructure in this region has led rise in demand for various fertility treatments such as IVF procedures, ICSI procedure etc.
Growth Factors:
- Increasing prevalence of infertility: The global prevalence of infertility is increasing due to various factors such as changing lifestyle, stress, and environmental pollution. This is expected to drive the demand for chronic gonadotropin products over the forecast period.
- Rising awareness about chronic gonadotropin therapy: There is a growing awareness among people about the benefits of chronic gonadotropin therapy for treating infertility issues. This is likely to boost demand for these products in the coming years.
- Technological advancements in chronic gonadotropin therapy: The technological advancements in chronic gonadotropin therapy are helping physicians to better understand and manage fertility issues using these products. This is anticipated to propel market growth during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Gonadotropin Market Research Report
By Type
Human Chronic Gonadotropin, Animal Chronic Gonadotropin
By Application
Hospital, Research Institutions, Others
By Companies
Bristol Mayer Squibb, Ferring, Fresenius Kabi, Merck, Actiza Pharmaceutical, Cigna, Sun Pharmaceutical, Lupin, Cipla, Zydus Cadila, Bristol Mayer Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Gonadotropin Market Report Segments:
The global Chronic Gonadotropin market is segmented on the basis of:
Types
Human Chronic Gonadotropin, Animal Chronic Gonadotropin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Mayer Squibb
- Ferring
- Fresenius Kabi
- Merck
- Actiza Pharmaceutical
- Cigna
- Sun Pharmaceutical
- Lupin
- Cipla
- Zydus Cadila
- Bristol Mayer Squibb
Highlights of The Chronic Gonadotropin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Human Chronic Gonadotropin
- Animal Chronic Gonadotropin
- By Application:
- Hospital
- Research Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Gonadotropin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic gonadotropin is a hormone that stimulates the production of testosterone and other male sex hormones.
Some of the key players operating in the chronic gonadotropin market are Bristol Mayer Squibb, Ferring, Fresenius Kabi, Merck, Actiza Pharmaceutical, Cigna, Sun Pharmaceutical, Lupin, Cipla, Zydus Cadila, Bristol Mayer Squibb.
The chronic gonadotropin market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Gonadotropin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Gonadotropin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Gonadotropin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Gonadotropin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Gonadotropin Market Size & Forecast, 2020-2028
4.5.1 Chronic Gonadotropin Market Size and Y-o-Y Growth
4.5.2 Chronic Gonadotropin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Human Chronic Gonadotropin
5.2.2 Animal Chronic Gonadotropin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research Institutions
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Gonadotropin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Gonadotropin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Human Chronic Gonadotropin
9.6.2 Animal Chronic Gonadotropin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research Institutions
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Human Chronic Gonadotropin
10.6.2 Animal Chronic Gonadotropin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research Institutions
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Human Chronic Gonadotropin
11.6.2 Animal Chronic Gonadotropin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research Institutions
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Human Chronic Gonadotropin
12.6.2 Animal Chronic Gonadotropin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research Institutions
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Human Chronic Gonadotropin
13.6.2 Animal Chronic Gonadotropin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research Institutions
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Gonadotropin Market: Competitive Dashboard
14.2 Global Chronic Gonadotropin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol Mayer Squibb
14.3.2 Ferring
14.3.3 Fresenius Kabi
14.3.4 Merck
14.3.5 Actiza Pharmaceutical
14.3.6 Cigna
14.3.7 Sun Pharmaceutical
14.3.8 Lupin
14.3.9 Cipla
14.3.10 Zydus Cadila
14.3.11 Bristol Mayer Squibb
